EANS-Adhoc: SYGNIS Pharma AG / SYGNIS Pharma AG successfully completes capital increase

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

10.08.2011

Ad-hoc release

SYGNIS Pharma AG successfully completes capital increase

Heidelberg, 10 August 2011 - The shareholders of SYGNIS Pharma AG
(Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard) exercised their
subscription and over- subscription rights for 3,076,623 new
no-par value bearer shares at a subscription price of euro 2.00
per new share by the end of the subscription period on 9 August
2011.

SYGNIS plans to use the gross proceeds of approximately euro 6.15
million from this capital increase to finance in particular the
completion and the potential commercialization of its current
efficacy trial of AX200 for the treatment of acute stroke (AXIS 2)
as well as the development of its preclinical KIBRA- project.

SYGNIS' main shareholder - dievini Hopp BioTech holding GmbH
& Co. KG, Walldorf, Germany - has exercised its subscription and
over-subscription rights for a total of 3 million new shares at the
subscription price. In receipt of these new shares dievini has
invested funds equal to the loan-amount dievini has committed in
June 2011. According to the contractual terms of the loan
agreement such commitment ceases to apply automatically with
this equity investment. As a result, dievini will hold
approximately 54,5% of shares outstanding in SYGNIS.

Following the entry of the capital increase in the Commercial
Register - which is scheduled for 15 August 2011 - the total number
of SYGNIS shares issued will increase to 16,829,504. Accordingly the
equity capital will increase from euro 13,752,881 to euro
16,829,504. The subscribed and allocated new SYGNIS shares are
expected to be delivered, after they have been listed on the
stock exchange, and to begin trading on the stock exchange on 17
August 2011. The capital increase is being conducted by Landesbank
Baden-Württemberg, Stuttgart, Germany.

For further information please contact:

|Dr. Franz-Werner Haas |
|Senior VP Operations |
|Tel: +49 (0) 6221-454 812 |
|Email: franz-Werner.haas@sygnis.de |

### Disclaimer
This publication is intended for information only and constitutes neither an
offer to sell nor an invitation to buy securities. The shares in SYGNIS Pharma
AG (the 'Shares') may not be offered or sold in the United States or to or for
the account or benefit of 'U.S. persons' (as such term is defined in Regulation
S under the U.S. Securities Act of 1933, as amended (the 'Securities Act')). No
offer or sale of transferable securities is being made to the public. The

shares are offered solely on the basis of subscription rights.

This document is only being distributed to and is only directed at
(i) persons who are outside the United Kingdom or (ii) to investment
professionals falling within Article 19(5) of the Financial Services
and Markets Act 2000 (Financial Promotion) Order 2005 (the 'Order')
or (iii) high net worth entities, and other persons to whom it may
lawfully be communicated, falling within Article 49(2)(a) to (d) of
the Order (all such persons together being referred to as 'relevant
persons'). The Shares are only available to, and any invitation,
offer or agreement to subscribe, purchase or otherwise acquire such
securities will be engaged in only with, relevant persons. Any person
who is not a relevant person should not act or rely on this document
or any of its contents.

Some statements included in this press release, relating neither to
proven financial results nor other historical data, should be viewed
as forward- looking, i.e. not definite. Such statements are mainly
predictions of future results, trends, plans or goals. These
statements should not be considered to be total guarantees since
given their very nature they are subject to known and unknown risks
and imponderability and can be affected by other factors as a
consequence of which the actual results, plans and goals of SYGNIS
Pharma AG may deviate greatly from the established conclusions or
implied predictions contained in such statements. SYGNIS does not
undertake to publicly update or revise these statements in the light
of new information or future results or for any other reason. ###

Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Stuttgart, Düsseldorf, Hannover, München
language: English